Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
81.84 USD | +0.09% | +1.93% | -0.72% |
Apr. 26 | Medtronic Receives FDA Approval for Inceptiv Spinal Cord Stimulator to Treat Chronic Pain | MT |
Apr. 26 | Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- The firm trades with high earnings multiples: 23.31 times its 2024 earnings per share.
- The company's enterprise value to sales, at 4.06 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.72% | 109B | C | ||
-3.57% | 184B | C+ | ||
-2.24% | 68.37B | A | ||
+4.61% | 51.56B | B- | ||
+9.47% | 44.69B | B- | ||
+4.37% | 41.49B | B+ | ||
+2.38% | 26.75B | B | ||
+4.03% | 26.7B | A- | ||
+15.38% | 25.68B | A- | ||
-0.48% | 24.8B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MDT Stock
- Ratings Medtronic plc